Infections Associated with Tumor Necrosis Factor‐α Antagonists
- 1 September 2005
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 25 (9) , 1181-1192
Abstract
Tumor necrosis factor‐α (TNF‐α) is a proinflammatory cytokine involved in a wide range of important physiologic processes. This cytokine has a pathologic role in some diseases, and TNF‐α antagonists are effective in treating inflammatory conditions. Given the putative role of TNF‐α in host defense against tuberculosis and other infections, the risk of infection with TNF‐α antagonists is a concern. Therefore, we searched the literature for reports of tuberculosis and other infections associated with TNF‐α–antagonist therapy. Although tuberculosis was rarely reported in randomized clinical comparisons of these antagonists, case reports and submissions to the MedWatch program of the United States Food and Drug Administration have been numerous. Most instances were associated with infliximab, but etanercept and adalimumab may also be associated with an increased risk of tuberculosis. Histoplasmosis, listeriosis, aspergillosis, coccidioidomycosis, and candidiasis have been associated with TNF‐α antagonists, but the causative relationship is not clear. Potential recipients of these drugs should be rigorously screened with skin testing, detailed questioning about recent travel and potential tuberculosis exposure, assessment for symptoms such as cough and weight loss, and chest radiography to minimize their risk of acquiring or reactivating tuberculosis. As with other immunosuppressant drugs, TNF‐α antagonists should not be given to patients with active infection.Keywords
This publication has 168 references indexed in Scilit:
- Cavitating pneumonia after treatment with infliximab and prednisoneEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Miliary tuberculosis after infliximab therapy in LebanonClinical Rheumatology, 2004
- Host innate defenses in the lung: the role of cytokinesCurrent Opinion in Infectious Diseases, 2003
- Tuberculous tonsillitis in a patient receiving etanercept treatmentAnnals of the Rheumatic Diseases, 2003
- Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activationAnnals of the Rheumatic Diseases, 2002
- Possible activation of an intramyocardial inflammatory process (Staphylococcus aureus) after treatment with infliximab in a boy with Crohn diseaseEuropean Journal of Pediatrics, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Invasive Pulmonary Aspergillosis Associated with Infliximab TherapyNew England Journal of Medicine, 2001
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Anti-Tumor Necrosis Factor Antibodies Inhibit the Influx of Granulocytes and Monocytes into an Inflammatory Exudate and Enhance the Growth of Listeria monocytogenes in Various OrgansThe Journal of Infectious Diseases, 1994